TABLE 7.
Barriers to the implementation of the 3HP regimen in HBC NTPs according to survey respondents
| Country | Barriers to 3HP implementation | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| High cost | No budget allocated | If no budget is allocated, are there plans for a budget? | NTP does not treat latent infection | Rifapentine is not registered in the country | Concerns about adverse effects of the regimen | Concerns about DDI between rifapentine and ARVs | Other | ||
| NTP has a policy for 3HP implementation | Cambodia | ||||||||
| Ethiopia* | 3HP adoption is not planned | ||||||||
| Indonesia | |||||||||
| Lesotho | |||||||||
| Liberia | (a) | Lack of training among healthcare workers. | |||||||
| Myanmar | |||||||||
| Nigeria* |
Availability of the regimen. Policy discussions regarding implementation are ongoing. |
||||||||
| Pakistan* | |||||||||
| Russia | |||||||||
| Thailand | |||||||||
| Vietnam | |||||||||
| Zambia | |||||||||
| Zimbabwe | Lack of funding for the training of healthcare workers. | ||||||||
| No current policy for 3HP implementation | Angola | ||||||||
| Bangladesh | Lack of policy for implementation. | ||||||||
| Brazil | |||||||||
| China | |||||||||
| DRC | |||||||||
| India | |||||||||
| Kenya | (b) | ||||||||
| Mozambique | |||||||||
| Philippines | |||||||||
| South Africa | |||||||||
| Tanzania |
Coordination issues with national AIDS program. In initial stages of pilot studies of implementation. |
||||||||
Barrier experienced in NTP ARV Antiretrovirals.
Unsure if barrier is experienced in NTP DDI Drug‐drug interactions.
Abbreviations: HBCs, high‐burden countries; NTP, national TB program.
(a) Currently updating national strategic plan, 3HP will be budgeted; (b) 3HP is in the process of being procured, and will run as a pilot before nation‐wide roll out.
a
Multiple respondents per country with differing responses regarding status of 3HP policy.